Evidence map›Paper›PMID 39905203›Full record

ArticleESC heart failure2025

Smartwatches in the assessment of heart failure patients in epidemiology and pathophysiology studies: A scoping review.

Solenn Fabien, Sandra Waechter, Gbenga A Kayode, Berno Müller, Marietta Roth, Friedrich Koehler

Abstract readScoping Review
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. [Telemedicine in chronic heart failure].Innere Medizin (Heidelberg, Germany) · 2025
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Solenn FabienCSL Vifor, Glattbrugg, Switzerland.ORCID https://orcid.org/0000-0003-4880-7105
Sandra WaechterCSL Vifor, Glattbrugg, Switzerland.ORCID https://orcid.org/0009-0007-3338-6607
Gbenga A KayodeCSL Behring, King of Prussia, Pennsylvania, United States.ORCID https://orcid.org/0000-0001-6313-010X
Berno MüllerCSL Vifor, Munich, Germany.
Marietta RothDepartment of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.ORCID https://orcid.org/0009-0003-7750-3845
Friedrich KoehlerDepartment of Cardiology, Angiology and Intensive Care Medicine, Centre for Cardiovascular Telemedicine, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany.ORCID https://orcid.org/0000-0003-0441-4123

Funding

Vifor International (AG)
6 · The paper itself

Abstract

A limited number of studies with smartwatches (SWs) investigated their potential in the field of heart failure (HF). The aim of this scoping review is to understand the extent of current literature on SWs in the HF population and the device's potential to improve disease management. The literature search was performed on PubMed and Embase in March 2024. Inclusion criteria included the use of commercialized SWs, HF diagnosis and peer-reviewed publications. Articles were excluded if the SW was not the study intervention or was part of a broader intervention programme. Reviews, case reports and study protocols were excluded. Of 1200 identified articles, 13 were included in the scoping review, encompassing 1171 patients with HF, and findings were presented in a descriptive summary table. Validity of several SW-collected physiological metrics was assessed against established technologies. Heart rate and step count measures were deemed moderately accurate in the HF population with Fitbit trackers (n = 5 patients, r = 0.54) and Garmin watches [n = 15 patients (mean age: 65.5 ± 12.6 years), concordance correlation coefficient (CCC) = 0.89 for Vivofit 1 and CCC = 0.92 for Vivofit 3], respectively, while calorimetry was the least reliable measurement [n = 19 patients (mean age: 65.1 ± 6.6 years), mean difference to indirect calorimeter: P = 0.01 for Fitbit Charge 2, P = 0.02 for Mio Slice]. Wrist-worn activity trackers were positively received by patients with HF [91.3% of adherence in research setting (n = 70 patients, median age (IQR): 79 years (76-82)), and 64% in real-world environment (n = 14 patients)] and their health-care providers (six cardiologists out of six acknowledged the data's usefulness), although device ownership ranged from 10 to 50% among the HF population. Physical activity information collected from SWs was found to be valuable in assisting cardiologists with their New York Heart Association (NYHA) functional class assessment, which is known for its limited objectivity and reproducibility. Multiple studies found that SWs, especially Fitbit devices, successfully identified a pattern where the degree of exercise intolerance increased with higher NYHA classes. These findings suggested that activity trackers can objectively evaluate the severity of physical activity limitations. As the functional classification of patients influences treatment strategies, SWs could serve as a valuable tool to facilitate and optimize outpatient disease management. SWs could be used as a complement to standard monitoring in HF. With continuous technological advances, it will be valuable to follow the deployment of SWs and to investigate their contribution to increased patient safety and consequently to health care cost reductions.

Indexed as

Fitness TrackersHeart FailureWearable Electronic DevicesHumansDisease managementHeart failureMobile healthSmartwatchesWearable devices

Identifiers

PMID39905203
PMCPMC12055391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.